Guest: Jill Terrien PhD, ANP-BCMusic Credit: Richard Onorato
In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.
In the last 3 decades, our improved knowledge of heart failure etiology has been the catalyst for major advances in its medical management. This session will help you to understand the modern pharmacologic treatment of patients with this syndrome and offer a peek into advances that can be expected in the coming years. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 2/8/2020, and they are subject to change as new information is published.
Heart failure is a global pandemic that continues to increase in prevalence. Despite the availability of established and novel therapies, mortality and morbidity in heart failure remains high. Join us for this overview of heart failure classification and pathophysiology, the evidence base supporting various treatments, and current guideline recommendations. Despite being the most common sustained arrhythmia in practice, the ideal management strategy for atrial fibrillation remains elusive for many clinicians. Accordingly, this session will review the classification and initial workup of patients with atrial fibrillation, with further discussion of the primary treatment goals. Stroke prevention therapies will be reviewed, along with means to achieve rate and rhythm control. Tune in to learn about ongoing gaps in the care of patients with heart failure and/or atrial fibrillation and how a standardized approach can help improve outcomes.
Heart failure (HF) affects more than 6 million Americans with approximately 50% mortality at 5 years. This session will show how recent advances in heart failure treatment have contributed to improved survival. This session will also discuss the guidelines, supporting evidence, and interventions to maximize hypertension management for individual patients. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 9/10/2020, and they are subject to change as new information is published.
Join cardiologist Ty Gluckman, MD in part two of this two-part podcast series as he reviews the unmet needs of patients with heart failure with reduced ejection fraction (HFrEF) and discusses the evidence on emerging pharmacologic treatments for HFrEF. He will describe the current data in HFrEF for the following drug classes: SGLT2 inhibitors, soluble guanylate cyclase stimulators, and selective cardiac myosin activators.